Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Study of Chimeric Antigen Receptor T-cell Therapy Targeting CD19 and BCMA (GC012F) in Patients With Relapsed/Refractory Multiple Myeloma

NCT06235229 is registered in ClinicalTrials.gov with Gracell Biotechnologies (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT06235229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06235229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Study of Chimeric Antigen Receptor T-cell Therapy Targeting CD19 and BCMA (GC012F) in Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 26, 2023
Completion date
March 2, 2026
Enrollment
110 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma